Increasing cases of genetic mutations are creating growth opportunities for the global “acute myeloid leukemia treatment“ market says fortune business Insights in a report, titled “Acute Myeloid Leukemia Treatment Market Size, Share and Global Trend By Disease Type (Myeloblastic, Promyelocytic, Myelomonocytic), By Treatment Type (Chemotherapy, Targeted Therapy, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography Forecast Till 2026.” Increasing investments in research and development by pharmaceuticals companies are driving the global acute myeloid leukemia treatment market
Request a Sample Copy of the Research Report:
FDA Approves XOSPATA®
Astellas Pharma Inc., a Japanese pharmaceutical company launched XOSPATA®, for the treatment of relapsed or refractory acute myeloid leukemia in adult patients. The new drug is FDA approved and will support in the treatment of patients with refractory or relapsed FLT3 mutation-positive (FLT3mut+) acute myeloid leukemia. The acute myeloid leukemia treatment market is predicted to witness high demand during the forecast period, owing to the launch of the advanced drug XOSPATA®. Several market players are launching drugs with FDA approval for the treatment of acute myeloid leukemia. For instance, Genentech, Inc. received FDA approval for the Venclexta for the treatment of patients who are newly-diagnosed with acute myeloid leukemia or patients who are not eligible for intensive induction chemotherapy. The aforementioned factors are contributing significantly to the global acute myeloid leukemia treatment market.
Increasing R&D Investments Toto Contribute Growth
The growingIncreasing cases of acute myeloid leukemia and unmet needs of patients, especially in emerging nations are leading towards the development ofencouraging the discovery of novel new drugs by pharmaceutical companies, which in turn is fostering the enabling growth of in the acute myeloid leukemia treatment market. Ffor instance, Pfizer Inc. launched Cglasdegib (Daurismo) with FDA approval, for patients who are newly-diagnosed with acute myeloid leukemia (AML). In 2019, according to the American Cancer Society, the number of new acute myeloid leukemia cases in the U.S estimated to be 21,450. The rising prevalence of genetic mutation, high exposure to radiations and sedentary lifestyles are some of the factors encouraging the cases of acute myeloid leukemia across the globe. In addition, product launches and rising investments in research and development activities by pharmaceutical companies are also predicted to foster growth for the global acute myeloid leukemia treatment market in the forthcoming year. Nonetheless, high risks of side effects associated with the use of drugs and expensive cost of stem cell transplantation are the factors restraining the growth of the global acute myeloid leukemia treatment market.
An Overview of the Impact of COVID-19 on this Market:
The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.
We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.
For More Information :
Leading Players operating in the Acute Myeloid Leukemia Treatment Market are:
Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
- VERASTEM, INC.,
- Genzyme Corporation,
- Neomed Management AS,
- Sunesis Pharmaceuticals Inc.,
- Pfizer Inc.,
- Bristol-Myers Squibb Company,
- Novartis AG,
- GlaxoSmithKline plc.,
North America to Emerge Dominate in the Global Market
Geographically, the global acute myeloid leukemia treatment market is segmented into North America, Europe, Asia- Pacific, Latin America, Middle East & Africa. North America is expected to dominate the global acute myeloid leukemia treatment market during the forecast period. Strategic research and development, excellent health reimbursement policies along with growing demand for advanced treatment I are boosting the market in the region. In Europe, the acute myeloid leukemia treatment market is predicted to grow at a significant rate, owing to the rising incidence of disease and active government aid. The Asia Pacific market is expected to grow at a remarkable CAGR during the forecast period owing to the increasing government expenditure for the treatment of cancer and developing healthcare infrastructure. In addition, rising inclination towards targeted therapies is expected to boost the growth of the global acute myeloid leukemia treatment market in the region in the forthcoming year.
Global Acute Myeloid Leukemia Treatment Market Segmentation :
By Disease Type
By Treatment Type
- Targeted Therapy
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- North America (USA and Canada)
- Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
- Latin America (Brazil, Mexico and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Reasons to Purchase this Report:
- Comprehensive analysis of the Acute Myeloid Leukemia Treatment Market growth drivers, obstacles, opportunities, and other related challenges.
- Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.
- Identifies market restraints and boosters.
- Identifies all the possible segments present in the market to aid organizations in strategic business planning.
Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/acute-myeloid-leukemia-treatment-market-100607
KEY QUESTIONS ANSWERED:
- What are the key technological and Acute Myeloid Leukemia Treatment Market trends shaping the market?
- What are the key opportunities in the market?
- What are the key companies operating in the market?
- Which company accounted for the highest market share?
- Why Choose Fortune Business Insights?
- What is the market size and growth rate of the global and regional market by various segments?
- What is the market size and growth rate of the market for selective countries?
- Which region or sub-segment is expected to drive the market in the forecast period?
- What Factors are estimated to drive and restrain the Acute Myeloid Leukemia Treatment Market growth?
More Trending Topics From Fortune Business [email protected]
Chronic Wound Care Market Size 2021 | To Reach USD 16.36 Billion with 6.2% by 2027; Increasing Investment in Technological Integration will Emerge in Favor of Market Growth, says Fortune Business Insights™
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune – 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Related Reports :